Sec Form 4 Filing - Morgan Bradley Paul @ CYTOKINETICS INC - 2017-08-31

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Morgan Bradley Paul 2. Issuer Name and Ticker or Trading Symbol CYTOKINETICS INC [ CYTK] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) SVP Drug Discovery & Early Dev (Last) (First) (Middle) 280 EAST GRAND AVENUE 3. Date of Earliest Transaction (MM/DD/YY) 08/31/2017 (Street) SOUTH SAN FRANCISCO, CA94080 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 08/31/2017 M( 1 ) 16,666 A $ 6.67 63,107 D Common Stock 08/31/2017 S( 2 ) 16,666 D $ 15 46,441 D Common Stock 08/31/2017 M( 1 ) 15,206 A $ 7.96 61,647 D Common Stock 08/31/2017 S( 2 ) 15,206 D $ 15 46,441 D Common Stock 08/31/2017 M( 1 ) 2,294 A $ 7.96 48,735 D Common Stock 08/31/2017 S( 2 ) 2,294 D $ 15 46,441 D Common Stock 08/31/2017 M( 1 ) 11,552 A $ 9.65 57,993 D Common Stock 08/31/2017 S( 2 ) 11,552 D $ 15 46,441 D Common Stock 08/31/2017 M( 1 ) 13,448 A $ 9.65 59,889 D Common Stock 08/31/2017 S( 2 ) 13,448 D $ 15 46,441 D Common Stock 08/31/2017 M( 1 ) 3,795 A $ 6 50,236 D Common Stock 08/31/2017 S( 2 ) 3,795 D $ 15 46,441 D Common Stock 08/31/2017 M( 1 ) 21,204 A $ 6 67,645 D Common Stock 08/31/2017 S( 2 ) 21,204 D $ 15 46,441 D Common Stock 08/31/2017 M( 1 ) 1,079 A $ 6.3 47,520 D Common Stock 08/31/2017 S( 2 ) 1,079 D $ 15 46,441 D Common Stock 08/31/2017 M( 1 ) 13,920 A $ 6.3 60,361 D Common Stock 08/31/2017 S( 2 ) 13,920 D $ 15 46,441 D Common Stock 08/31/2017 M( 1 ) 617 A $ 9.42 47,058 D Common Stock 08/31/2017 S( 2 ) 617 D $ 15 46,441 D Common Stock 08/31/2017 M( 1 ) 11,883 A $ 9.42 58,324 D Common Stock 08/31/2017 S( 2 ) 11,883 D $ 15 46,441 D Common Stock 08/31/2017 M( 1 ) 694 A $ 11.1 47,135 D Common Stock 08/31/2017 S( 2 ) 694 D $ 15 46,441 D Common Stock 08/31/2017 M( 1 ) 2,639 A $ 11.1 49,080 D Common Stock 08/31/2017 S( 2 ) 2,639 D $ 15 46,441 D Common Stock 08/31/2017 M( 1 ) 695 A $ 11.1 47,136 D Common Stock 08/31/2017 S( 2 ) 695 D $ 15 46,441 D Common Stock 08/31/2017 M( 1 ) 2,638 A $ 11.1 49,079 D Common Stock 08/31/2017 S( 2 ) 2,638 D $ 15 46,441 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Incentive Stock Option (right to buy) $ 6 08/31/2017 M 21,204 04/05/2013 03/05/2023 Common Stock 21,204 $ 0 0 D Incentive Stock Option (right to buy) $ 6.3 08/31/2017 M 13,920 04/05/2012 03/05/2022 Common Stock 13,920 $ 0 0 D Incentive Stock Option (right to buy) $ 7.96 08/31/2017 M 2,294 03/26/2015 02/26/2025 Common Stock 2,294 $ 0 8,750 D Incentive Stock Option (right to buy) $ 9.42 08/31/2017 M 11,883 03/28/2011 02/28/2021 Common Stock 11,883 $ 0 0 D Incentive Stock Option (right to buy) $ 9.65 08/31/2017 M 13,448 03/24/2014 02/24/2024 Common Stock 13,448 $ 0 5,000 D Incentive Stock Option (right to buy) $ 11.1 08/31/2017 M 2,639 03/26/2009 02/26/2019 Common Stock 2,639 $ 0 2,638 D Incentive Stock Option (right to buy) $ 11.1 08/31/2017 M 2,638 03/26/2009 02/26/2019 Common Stock 2,638 $ 0 0 D Non-Qualified Stock Option (right to buy) $ 6 08/31/2017 M 3,795 04/05/2013 03/05/2023 Common Stock 3,795 $ 0 0 D Non-Qualified Stock Option (right to buy) $ 6.3 08/31/2017 M 1,079 04/05/2012 03/05/2022 Common Stock 1,079 $ 0 0 D Non-Qualified Stock Option (right to buy) $ 6.67 08/31/2017 M 16,666 03/23/2016 02/23/2026 Common Stock 16,666 $ 0 14,517 D Non-Qualified Stock Option (right to buy) $ 7.96 08/31/2017 M 15,206 03/26/2015 02/26/2025 Common Stock 15,206 $ 0 3,750 D Non-Qualified Stock Option (right to buy) $ 9.42 08/31/2017 M 617 03/28/2011 02/28/2021 Common Stock 617 $ 0 0 D Non-Qualified Stock Option (right to buy) $ 9.65 08/31/2017 M 11,552 03/24/2014 02/24/2024 Common Stock 11,552 $ 0 0 D Non-Qualified Stock Option (right to buy) $ 11.1 08/31/2017 M 694 03/26/2009 02/26/2019 Common Stock 694 $ 0 695 D Non-Qualified Stock Option (right to buy) $ 11.1 08/31/2017 M 695 03/26/2009 02/26/2019 Common Stock 695 $ 0 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Morgan Bradley Paul 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO, CA94080 SVP Drug Discovery & Early Dev Signatures Bradley Morgan 09/01/2017 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The exercise(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017. ( 2 )The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2017.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.